Kymera Therapeutics is a clinical stage biopharmaceutical company pioneering a transformative new modality, “targeted protein degradation” (TPD), with the ability to pursue targets long considered undruggable and to treat disease in entirely new ways. Our team has developed a proprietary drug discovery engine, Pegasus, to enable the design of highly selective, small molecule protein degraders with potent activity against a broad range of disease indications. We are committed to selecting targets with the broadest possible impact across multiple disease indications with high unmet medical need to realize the full potential of TPD. Kymera is led by an expert team of dedicated scientists and drug hunters, with decades of experience in the foundational areas of targeted protein degradation and drug development.read more
Where This Score Ranks Kymera Therapeutics' Environment
TOP
20%
In the Top 20% of 1704 similar size companies on Comparably
TOP
15%
In the Top 15% of 205 companies in Boston
?
Not enough ratings to compare against competitors
The environment at Kymera Therapeutics is considered positive by 67% of employees and regarded as having an “extremely fast” work pace by 5 employees. Kymera Therapeutics ranks in the Top 20% of 1704 similar sized companies (51-200 Employees) on Comparably and Top 15% of 205 companies in Boston.
Rate Environment the Highest
Not Enough Ratings To Show Who Ranks Environment the Highest